Chemical and biological evaluation of dipeptidyl boronic acid proteasome inhibitors for use in prodrugs and pro-soft drugs targeting solid tumors.

Bortezomib, a dipeptidyl boronic acid and potent inhibitor of the 26S proteasome, is remarkably effective against multiple myeloma (MM) but not against solid tumors. Dose-limiting adverse effects from "on target" inhibition of the proteasome in normal cells and tissues appear to be a key obstacle. Achieving efficacy against solid tumors therefore is likely to require making the inhibitor more selective for tumor tissue over normal tissues. The simplest strategy that might provide such tissue specificity would be to employ a tumor specific protease to release an inhibitor from a larger, noninhibitory structure. However, such release would necessarily generate an inhibitor with a free N-terminal amino group, raising a key question: Can short peptide boronic acids with N-terminal amino groups have the requisite properties to serve as warheads in prodrugs? Here we show that dipeptides of boroLeu, the smallest plausible candidates for the task, can indeed be sufficiently potent, cell-penetrating, cytotoxic, and stable to degradation by cellular peptidases to serve in this capacity.

[1]  J. Lai,et al.  Pro-soft Val-boroPro: a strategy for enhancing in vivo performance of boronic acid inhibitors of serine proteases. , 2011, Journal of medicinal chemistry.

[2]  Jonathan L Blank,et al.  Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome. , 2010, Bioorganic & medicinal chemistry letters.

[3]  C. Cohen,et al.  Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma , 2010, Diagnostic pathology.

[4]  T. Soucy,et al.  Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit , 2010, The Biochemical journal.

[5]  David J Newman,et al.  The odyssey of marine pharmaceuticals: a current pipeline perspective. , 2010, Trends in pharmacological sciences.

[6]  T. Ling,et al.  Concise formal synthesis of (-)-salinosporamide A (marizomib) using a regio- and stereoselective epoxidation and reductive oxirane ring-opening strategy. , 2010, The Journal of organic chemistry.

[7]  D. Chauhan,et al.  Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI‐0052 (marizomib) in a human plasmacytoma xenograft murine model , 2010, British journal of haematology.

[8]  K. S. Lam,et al.  Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides , 2010, Marine drugs.

[9]  L. Dick,et al.  Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. , 2010, Drug discovery today.

[10]  M. Rolfe,et al.  Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. , 2010, Cancer research.

[11]  Yi Xia,et al.  Therapeutic potential of boron-containing compounds. , 2009, Future medicinal chemistry.

[12]  B. Moore,et al.  Advances in and applications of proteasome inhibitors. , 2008, Current opinion in chemical biology.

[13]  Bradley S Moore,et al.  Mutasynthesis of fluorosalinosporamide, a potent and reversible inhibitor of the proteasome. , 2008, Angewandte Chemie.

[14]  D. Matteson.  α‐Amido boronic acids: A synthetic challenge and their properties as serine protease inhibitors , 2008 .

[15]  C. Alden,et al.  Effect of an experimental proteasome inhibitor on the cytoskeleton, cytosolic protein turnover, and induction in the neuronal cells in vitro. , 2008, Neurotoxicology.

[16]  Richard Pazdur,et al.  Bortezomib for the Treatment of Mantle Cell Lymphoma , 2007, Clinical Cancer Research.

[17]  A. Goy.  Mantle cell lymphoma: Evolving novel options , 2007, Current oncology reports.

[18]  A. Goy,et al.  Expanding therapeutic options in mantle cell lymphoma. , 2007, Clinical lymphoma & myeloma.

[19]  Matthias D Hofer,et al.  Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. , 2007, Human pathology.

[20]  M. Groll,et al.  20S proteasome and its inhibitors: crystallographic knowledge for drug development. , 2007, Chemical reviews.

[21]  P. Richardson,et al.  Proteasome inhibition as a new therapeutic principle in hematological malignancies. , 2006, Current drug targets.

[22]  R. Orlowski,et al.  The proteasome and proteasome inhibitors in cancer therapy. , 2006, Annual review of pharmacology and toxicology.

[23]  S. Demo,et al.  Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. , 2005, Blood.

[24]  D. Hall.  Boronic acids : preparation and applications in organic synthesis and medicine , 2005 .

[25]  J. Lai,et al.  Autochelation in dipeptide boronic acids: pH-dependent structures and equilibria of Asp-boroPro and His-boroPro by NMR spectroscopy. , 2005, Journal of the American Chemical Society.

[26]  A. Canutescu,et al.  Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth , 2005, Molecular Cancer Therapeutics.

[27]  D. Wolf,et al.  Death gives birth to life: the essential role of the ubiquitin-proteasome system in biology. , 2004, Biochimica et biophysica acta.

[28]  D. Wolf,et al.  The proteasome: a proteolytic nanomachine of cell regulation and waste disposal. , 2004, Biochimica et biophysica acta.

[29]  A. Goy,et al.  Update on the proteasome inhibitor bortezomib in hematologic malignancies. , 2004, Clinical lymphoma.

[30]  N. Bodor,et al.  Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites , 2004, Molecular biotechnology.

[31]  Richard Pazdur,et al.  Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. , 2003, The oncologist.

[32]  M. Groll,et al.  Molecular shredders: how proteasomes fulfill their role. , 2003, Current opinion in structural biology.

[33]  S. Badve,et al.  Expression of androgen receptor and prostate-specific antigen in male breast carcinoma , 2003, Breast Cancer Research.

[34]  M. Borad,et al.  The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  T. Mincer,et al.  Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. , 2003, Angewandte Chemie.

[36]  D. Neuberg,et al.  Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. , 2002, Cancer research.

[37]  P. Elliott,et al.  Proteasome inhibition measurements: clinical application. , 2000, Clinical chemistry.

[38]  N. Bodor,et al.  Soft drug design: General principles and recent applications , 2000, Medicinal research reviews.

[39]  J. Park,et al.  Fibroblast Activation Protein, a Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fibroblasts* , 1999, The Journal of Biological Chemistry.

[40]  C. Crews,et al.  Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide α', β'-epoxyketones , 1999 .

[41]  C. Abbott,et al.  Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis , 1999, Hepatology.

[42]  E. Sausville,et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.

[43]  L. Dick,et al.  Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. , 1998, Bioorganic & medicinal chemistry letters.

[44]  J. Broers,et al.  Detailed analysis of cell cycle kinetics upon proteasome inhibition. , 1997, Cytometry.

[45]  A. Goldberg,et al.  Lactacystin and clasto-Lactacystin β-Lactone Modify Multiple Proteasome β-Subunits and Inhibit Intracellular Protein Degradation and Major Histocompatibility Complex Class I Antigen Presentation* , 1997, The Journal of Biological Chemistry.

[46]  C. Kettner,et al.  New Asymmetric Synthesis of α-Aminoboronic Acids Containing Functionalized Side Chains , 1996 .

[47]  S. J. Campbell,et al.  Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides. , 1996, Journal of medicinal chemistry.

[48]  L. Dick,et al.  Kinetic characterization of the chymotryptic activity of the 20S proteasome. , 1996, Biochemistry.

[49]  U. Günther,et al.  Solution structures of the DP IV (CD26) inhibitor Val‐boroPro determined by NMR spectroscopy , 1995 .

[50]  Charles A. Kennedy,et al.  Studies on Proline Boronic Acid Dipeptide Inhibitors of Dipeptidyl Peptidase IV: Identification of a Cyclic Species Containing a B-N Bond , 1994 .

[51]  U. Günther,et al.  Solution structures of active and inactive forms of the DP IV (CD26) inhibitor Pro-boroPro determined by NMR spectroscopy. , 1994, Biochemistry.

[52]  R. Snow,et al.  Two efficient methods for the cleavage of pinanediol boronate esters yielding the free boronic acids , 1994 .

[53]  J. Kleinschmidt,et al.  Distinct 19 S and 20 S subcomplexes of the 26 S proteasome and their distribution in the nucleus and the cytoplasm. , 1994, The Journal of biological chemistry.

[54]  Charles A. Kennedy,et al.  Immunosuppresive boronic acid dipeptides: correlation between conformation and activity , 1993 .

[55]  M. Rechsteiner,et al.  The multicatalytic and 26 S proteases. , 1993, The Journal of biological chemistry.

[56]  A. Rivett,et al.  Electron microscopic localization of the multicatalytic proteinase complex in rat liver and in cultured cells. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[57]  B. Huber,et al.  Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[58]  L. Old,et al.  Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[59]  M. Melamed,et al.  Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[60]  D. Matteson,et al.  A practical synthesis of (dichloromethyl)- and (1,1-dichloroethyl)boronic esters , 1986 .

[61]  D. Matteson,et al.  Asymmetric synthesis with boronic esters , 1985 .

[62]  N. Bodor,et al.  Soft drugs: Principles and methods for the design of safe drugs , 1984, Medicinal research reviews.

[63]  D. Matteson,et al.  SYNTHESIS AND PROPERTIES OF PINANEDIOL α-AMIDO BORONIC ESTERS , 1984 .

[64]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[65]  N. Bodor,et al.  Soft drugs V: Thiazolidine-type derivatives of progesterone and testosterone. , 1982, Journal of pharmaceutical sciences.

[66]  Nicholas Bodor,et al.  Soft drugs 4. 3-Spirothiazolidines of hydrocortisone and its derivatives , 1982 .

[67]  C. Hill,et al.  Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. , 2005, Trends in cell biology.

[68]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[69]  K. Scherrer,et al.  The prosomes (multicatalytic proteinases; proteasomes) and their relationship to the untranslated messenger ribonucleoproteins, the cytoskeleton, and cell differentiation. , 1994, Progress in nucleic acid research and molecular biology.